髓样分化因子88多态性的研究进展

doi:10.3969/j.issn.1673-8640.2020.04.020

摘要/Abstract

摘要：

髓样分化因子88（MYD88）是细胞内传递信号的关键衔接蛋白,可介导多种Toll样受体（TLR）、白细胞介素1受体（IL-1R）及白细胞介素-18受体（IL-18R）的信号传递,在固有免疫中发挥显著作用。MYD88依赖通路在多种病原体致病过程中发挥作用,与肿瘤、感染性疾病、自身免疫性疾病等密切相关。MYD88依赖通路被认为是这些疾病治疗的关键靶点。MYD88基因 L265P突变导致MYD88蛋白Toll-白细胞介素1受体域（TIR）的265位氨基酸发生改变。该突变可通过加强核因子-κB（NF-κB）等转录因子促进酪氨酸激酶-信号转导子和转录激活子3（JAK-STAT3）信号通路传导,介导白细胞介素（IL）-6、IL-10及β-干扰素（IFN-β）等炎症因子的产生。文章从MYD88的结构、基本功能、在信号传导通路中的作用以及MYD88基因L265P突变与疾病的关联等方面进行综述。

关键词: 髓样分化因子88, Toll样受体, 淋巴浆细胞淋巴瘤

Abstract:

Myeloid differentiation factor 88（MYD88）is an important adaptor protein mediating the signal transduction of Toll-like receptors（TLR）,interleukin 1 receptor（IL-1R）and interleukin 18 receptor（IL-18R）,which plays a key role in innate immunity. MYD88-dependent pathways play roles in the pathogenesis of multiple pathogens and have relations with tumors,infectious diseases,autoimmune diseases and so on,which are considered to be important targets for the intervention of these diseases. The L265P mutant in MYD88,an amino acid change（L265P）in the MYD88 Toll-like receptor/interleukin 1 receptor（TIR）,promotes Janus kinase-signal transducer and activator of transcription 3（JAK-STAT3） signaling pathway by enhancing transcription factors such as nuclear factor kappa B（NF-κB）,and mediates the production of inflammatory factors such as interleukin（IL）-6,IL-10 and interferon-beta（IFN-β）. The structure and fundamental function of MYD88 and its role in signal transduction are reviewed. Furthermore,the association between MYD88 L265P and diseases are also illustrated.

Key words: Myeloid differentiation factor 88, Toll-like receptor, Lymphoplasmacytoid lymphoma

中图分类号:

R446.1

胡玉懿, 陈朴综述, 郭玮, 潘柏申审校. 髓样分化因子88多态性的研究进展[J]. 检验医学, 2020, 35(4): 380-386.

HU Yuyi, CHEN Pu, GUO Wei, PAN Baishen. Research progress of myeloid differentiation factor 88 polymorphism[J]. Laboratory Medicine, 2020, 35(4): 380-386.

图/表 2

参考文献 46.

1.	袁西华,陈昌辉. 髓样分化蛋白-2在转导内毒素信号中的作用及临床意义[J]. 实用儿科临床杂志,2010,25(6):451-454.
2.	SHEEDY F J,O'NEILL L A. The troll in toll:mal and tram as bridges for TLR2 and TLR4 signaling[J]. J Leukoc Biol,2007,82(2):196-203.
3.	ZHAN C,QI R,WEI G,et al.Conformational dynamics of cancer-associated MyD88-TIR domain mutant L252P (L265P) allosterically tilts the landscape toward homo-dimerization[J]. Protein Eng Des Sel,2016,29(9):347-354.
4.	LANDGREN O,TAGEJA N.MYD88 and beyond:novel opportunities for diagnosis,prognosis and treatment in Waldenström's macroglobulinemia[J]. Leukemia,2014,28(9):1799-1803.
5.	SONG D H,LEE J O.Sensing of microbial molecular patterns by Toll-like receptors[J]. Immunol Rev,2012,250(1):216-229.
6.	AHMED-HASSAN H,ABDUL-CADER M S,SABRY M A,et al.Toll-like receptor(TLR) 4 signalling induces myeloid differentiation primary response gene(MYD)88 independent pathway in avian species leading to type Ⅰ interferon production and antiviral response[J]. Virus Res,2018,256:107-116.
7.	VALKOV E,STAMP A,DIMAIO F,et al.Crystal structure of Toll-like receptor adaptor MAL/TIRAP reveals the molecular basis for signal transduction and disease protection[J]. Proc Natl Acad Sci U S A,2011,108(36):14879-14884.
8.	LOIARRO M,VOLPE E,RUGGIERO V,et al.Mutational analysis identifies residues crucial for homodimerization of myeloid differentiation factor 88 (MyD88) and for its function in immune cells[J]. J Biol Chem,2013,288(42):30210-30222.
9.	WANG J Q,JEELALL Y S,FERGUSON L L,et al.Toll-like receptors and cancer:MYD88 mutation and inflammation[J]. Front Immunol,2014,5:367.
10.	CAPELLUTO D G.Tollip:a multitasking protein in innate immunity and protein trafficking[J]. Microbes Infect,2012,14(2):140-147.
11.	MOTSHWENE P G,MONCRIEFFE M C,GROSSMANN JG,et al.An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4[J]. J Biol Chem,2009,284(37):25404-25411.
12.	O'NEILL L A. The interleukin-1 receptor/Toll-like receptor superfamily:10 years of progress[J]. Immunol Rev,2008,226:10-18.
13.	JIN B,SUN T,YU X H,et al.The effects of TLR activation on T-cell development and differentiation[J]. Clin Dev Immunol,2012,2012:836485.
14.	TREON S P,XU L,YANG G,et al.MYD88 L265P somatic mutation in Waldenström's macroglobulinemia[J]. N Engl J Med,2012,367(9):826-833.
15.	NGO V N,YOUNG R M,SCHMITZ R,et al.Oncogenically active MYD88 mutations in human lymphoma[J]. Nature,2011,470(7332):115-119.
16.	JARDIN F.Next generation sequencing and the management of diffuse large B-cell lymphoma:from whole exome analysis to targeted therapy[J]. Discov Med,2014,18(97):51-65.
17.	XU L,HUNTER Z R,YANG G,et al.MYD88 L265P in Waldenström macroglobulinemia,IgM monoclonal gammopathy,and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction[J]. Blood,2013,121(11):2051-2058.
18.	邹德慧,易树华,刘慧敏,等. 非 IgM型淋巴浆细胞淋巴瘤临床及生物学特征研究[J]. 中华血液学杂志,2015,36(6):493-496.
19.	TREON S P,HUNTER Z R,CASTILLO J J,et al.Waldenström macroglobulinemia[J]. Hematol Oncol Clin North Am,2014,28(5):945-970.
20.	KAWAI T,AKIRA S.The role of pattern-recognition receptors in innate immunity:update on Toll-like receptors[J]. Nat Immunol,2010,11(5):373-384.
21.	GACHARD N,PARRENS M,SOUBEYRAN I,et al.IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas[J]. Leukemia,2013,27(1):183-189.
22.	LI S,YOUNG K H,MEDEIROS L J,et al.Diffuse large B-cell lymphoma[J]. Pathology,2018,50(1):74-87.
23.	朱雄增,李小秋. 解读2008年恶性淋巴瘤WHO分类[J]. 临床与实验病理学杂志, 2010,26(1):10-13.
24.	ROVIRA J,KARUBE K,VALERA A,et al.MYD88 L265P mutations,but no other variants,identify a subpopulation of DLBCL patients of activated B-cell origin,extranodal involvement,and poor outcome[J]. Clin Cancer Res,2016,22(11):2755-2764.
25.	KING R L,GONSALVES W I,ANSELL S M,et al.Lymphoplasmacytic lymphoma with a non-IgM paraprotein shows clinical and pathologic heterogeneity and may harbor MYD88 L265P mutations[J]. Am J Clin Pathol,2016,145(6):843-851.
26.	ANSELL S M,HODGE L S,SECRETO F J,et al.Activation of TAK1 by MYD88 L265P drives malignant B-cell growth in non-Hodgkin lymphoma[J]. Blood Cancer J,2014,4(2):e183.
27.	QIU H,GONG S,XU L,et al.MYD88 L265P mutation promoted malignant B cell resistance against T cell-mediated cytotoxicity via upregulating the IL-10/STAT3 cascade[J]. Int Immunopharmacol,2018,64:394-400.
28.	PUENTE X S,PINYOL M,QUESADA V,et al.Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia[J]. Nature,2011,475(7354):101-105.
29.	李航宇,孙宏治,李岩,等. TLR2和TLR4在肝细胞癌中的表达及其与增殖效应因子之间的关系[J].中国现代医学杂志,2014,24(27):1-8.
30.	LI P M,LI Y L,LIU B,et al.Curcumin inhibits MHCC97H liver cancer cells by activating ROS/TLR-4/caspase signaling pathway[J]. Asian Pac J Cancer Prev,2014,15(5):2329-2334.
31.	KANG Y,SU G,SUN J,et al.Activation of the TLR4/MyD88 signaling pathway contributes to the development of human hepatocellular carcinoma via upregulation of IL-23 and IL-17A[J]. Oncol Lett,2018,15(6):9647-9654.
32.	SHAHRIARI S,REZAEIFARD S,MOGHIMI H R,et al.Cell membrane and intracellular expression of toll-like receptor 9(TLR9) in colorectal cancer and breast cancer cell-lines[J]. Cancer Biomark,2017,18(4):375-380.
33.	WU K,ZHANG H,FU Y,et al.TLR4/MyD88 signaling determines the metastatic potential of breast cancer cells[J]. Mol Med Rep,2018,18(3):3411-3420.
34.	CHEN X,ZHAO F,ZHANG H,et al.Significance of TLR4/MyD88 expression in breast cancer[J]. Int J Clin Exp Pathol,2015,8(6):7034-7039.
35.	HOLTORF A,CONRAD A,HOLZMANN B,et al.Cell-type specific MyD88 signaling is required for intestinal tumor initiation and progression to malignancy[J]. Oncoimmunology,2018,7(8):e1466770.
36.	KOHTZ P D,HALPERN A L,ELDEIRY M A,et al.Toll-like receptor-4 is a mediator of proliferation in esophageal adenocarcinoma[J]. Ann Thorac Surg,2019,107(1):233-241.
37.	WANG L,YU K,ZHANG X,et al.Dual functional roles of the MyD88 signaling in colorectal cancer development[J]. Biomed Pharmacother,2018,107:177-184.
38.	刘月宾. TLR4及NF-κBp65在食管癌组织中的表达及其临床意义[D]. 泸州:泸州医学院,2011.
39.	HOSHI N,SCHENTEN D,NISH S A,et al.MyD88 signaling in colonic mononuclear phagocytes drives colitis in IL-10-deficient mice[J]. Nat Commun,2012,3:1120.
40.	ZHOU M,XU W,WANG J,et al.Boosting mTOR-dependent autophagy via upstream TLR4-MyD88-MAPK signalling and downstream NF-κB pathway quenches intestinal inflammation and oxidative stress injury[J]. EBioMedicine,2018,35:345-360.
41.	SINGH M V, SWAMINATHAN P D,LUCZAK E D,et al.MyD88 mediated inflammatory signaling leads to CaMKⅡ oxidation,cardiac hypertrophy and death after myocardial infarction[J]. J Mol Cell Cardiol,2012,52(5):1135-1144.
42.	FENG Y,ZOU L,CHEN C,et al.Role of cardiac- and myeloid-MyD88 signaling in endotoxin shock:a study with tissue-specific deletion models[J]. Anesthesiology,2014,121(6):1258-1269.
43.	张金萍,陈超,杨毅. Toll样受体2和4在新生儿感染时的变化及其临床意义[J]. 中华儿科杂志,2007,45(2):130-133.
44.	WEBER A N R,CARDONA GLORIA Y,ÇINAR Ö,et al. Oncogenic MYD88 mutations in lymphoma:novel insights and therapeutic possibilities[J]. Cancer Immunol Immunother,2018,67(11):1797-1807.
45.	梁小明, 陈昌辉. 髓样分化因子88 在Toll 样受体信号通路中的作用及临床意义[J]. 实用儿科临床杂志, 2012, 27(15):1197-1200.
46.	ZAMBIRINIS C P,MILLER G.Signaling via MYD88 in the pancreatic tumor microenvironment:a double-edged sword[J]. Oncoimmunology,2013,2(1):e22567.

[1]	任媛, 张敏, 殷翔, 曾倩雯. 肠道菌群对慢性荨麻疹患者血清炎症因子的影响[J]. 检验医学, 2021, 36(5): 504-509.
[2]	樊明鹤, 林广民, 黄瑞杰. TLR4 mRNA和HO-1水平在ICVD病情及预后评估中的价值[J]. 检验医学, 2021, 36(12): 1229-1233.
[3]	闫佩毅, 张骥, 涂焕平, 张立, 仇越, 张锋英, 胡奕雯, 金姝. COPD患者痰液中性粒细胞氧化吞噬功能及相关受体变化的临床意义[J]. 检验医学, 2020, 35(6): 570-577.
[4]	吕迎霞, 杨俊梅, 郑莉娟, 黄庆华. SLE患儿外周血TLR-4、HMGB1的表达及临床意义[J]. 检验医学, 2020, 35(11): 1143-1146.
[5]	李懿皞, 周琰, 陈朴, 胡玉懿, 王蓓丽, 郭玮, 潘柏申. MyD88 基因L265P突变检测辅助诊断淋巴浆细胞淋巴瘤/华氏巨球蛋白血症1例[J]. 检验医学, 2018, 33(9): 865-867.
[6]	李利燕, 李洪春, 马萍. 穿心莲内酯在铜绿假单胞菌诱导的大鼠肺部感染模型中的抗炎作用及其作用机制[J]. 检验医学, 2014, 29(5): 535-539.
[7]	钱　雷;汪晓莺;吕丽君;陈德训 . 类风湿性关节炎患者早期外周血单个核细胞Toll样受体2、4表达及意义[J]. 检验医学, 2012, 27(8): 659-662.